353 related articles for article (PubMed ID: 21051986)
1. Human papillomavirus messenger RNA assay for cervical cancer screening: the Shenzhen Cervical Cancer Screening Trial I.
Wu R; Belinson SE; Du H; Na W; Qu X; Wu R; Liu Y; Wang C; Zhou Y; Zhang L; Belinson JL
Int J Gynecol Cancer; 2010 Nov; 20(8):1411-4. PubMed ID: 21051986
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany.
Iftner T; Neis KJ; Castanon A; Landy R; Holz B; Woll-Herrmann A; Iftner A; Staebler A; Wallwiener D; Hann von Weyhern C; Neis F; Haedicke-Jarboui J; Martus P; Brucker S; Henes M; Sasieni P
J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30355760
[TBL] [Abstract][Full Text] [Related]
3. Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany.
Iftner T; Becker S; Neis KJ; Castanon A; Iftner A; Holz B; Staebler A; Henes M; Rall K; Haedicke J; von Weyhern CH; Clad A; Brucker S; Sasieni P
J Clin Microbiol; 2015 Aug; 53(8):2509-16. PubMed ID: 26019212
[TBL] [Abstract][Full Text] [Related]
4. The clinical performance of APTIMA human papillomavirus and Hybrid Capture 2 assays in the triage of lesser abnormal cervical cytologies.
Guo Y; You K; Geng L; Qiao J
J Gynecol Oncol; 2014 Oct; 25(4):287-92. PubMed ID: 25142625
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity of APTIMA HPV E6/E7 mRNA test in comparison with hybrid capture 2 HPV DNA test for detection of high risk oncogenic human papillomavirus in 396 biopsy confirmed cervical cancers.
Basu P; Banerjee D; Mittal S; Dutta S; Ghosh I; Chowdhury N; Abraham P; Chandna P; Ratnam S
J Med Virol; 2016 Jul; 88(7):1271-8. PubMed ID: 26693677
[TBL] [Abstract][Full Text] [Related]
6. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection.
Nieves L; Enerson CL; Belinson S; Brainard J; Chiesa-Vottero A; Nagore N; Booth C; Pérez AG; Chávez-Avilés MN; Belinson J
Int J Gynecol Cancer; 2013 Mar; 23(3):513-8. PubMed ID: 23334437
[TBL] [Abstract][Full Text] [Related]
7. Efficiency of the APTIMA HPV Assay for detection of HPV RNA and DNA targets.
Getman D; Aiyer A; Dockter J; Giachetti C; Zhang F; Ginocchio CC
J Clin Virol; 2009 Jul; 45 Suppl 1():S49-54. PubMed ID: 19651369
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus oncogenic mRNA testing for cervical cancer screening: baseline and longitudinal results from the CLEAR study.
Reid JL; Wright TC; Stoler MH; Cuzick J; Castle PE; Dockter J; Getman D; Giachetti C
Am J Clin Pathol; 2015 Sep; 144(3):473-83. PubMed ID: 26276778
[TBL] [Abstract][Full Text] [Related]
9. Detection of human papillomavirus 16, 18, and 45 in women with ASC-US cytology and the risk of cervical precancer: results from the CLEAR HPV study.
Castle PE; Cuzick J; Stoler MH; Wright TC; Reid JL; Dockter J; Giachetti C; Getman D
Am J Clin Pathol; 2015 Feb; 143(2):160-7. PubMed ID: 25596241
[TBL] [Abstract][Full Text] [Related]
10. Comparative performance of human papillomavirus messenger RNA versus DNA screening tests at baseline and 48 months in the HPV FOCAL trial.
Cook DA; Smith LW; Law JH; Mei W; Gondara L; van Niekerk DJ; Ceballos KM; Jang D; Chernesky M; Franco EL; Ogilvie GS; Coldman AJ; Krajden M
J Clin Virol; 2018 Nov; 108():32-37. PubMed ID: 30223252
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study.
Monsonego J; Hudgens MG; Zerat L; Zerat JC; Syrjänen K; Halfon P; Ruiz F; Smith JS
Int J Cancer; 2011 Aug; 129(3):691-701. PubMed ID: 20941740
[TBL] [Abstract][Full Text] [Related]
12. Performance of human papillomavirus E6/E7 mRNA assay for primary cervical cancer screening and triage: Population-based screening in China.
Zhang J; Yang D; Cui X; Liu G; Cui Z; Wang C; Piao H
Front Cell Infect Microbiol; 2022; 12():935071. PubMed ID: 36105144
[TBL] [Abstract][Full Text] [Related]
13. Increased HPV detection by the use of a pre-heating step on vaginal self-samples analysed by Aptima HPV assay.
Borgfeldt C; Forslund O
J Virol Methods; 2019 Aug; 270():18-20. PubMed ID: 31002831
[TBL] [Abstract][Full Text] [Related]
14. Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study).
Monsonego J; Hudgens MG; Zerat L; Zerat JC; Syrjänen K; Smith JS
Gynecol Oncol; 2012 Apr; 125(1):175-80. PubMed ID: 22233689
[TBL] [Abstract][Full Text] [Related]
15. Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types.
Verdoodt F; Szarewski A; Halfon P; Cuschieri K; Arbyn M
Cancer Cytopathol; 2013 Dec; 121(12):675-87. PubMed ID: 23881840
[TBL] [Abstract][Full Text] [Related]
16. HPV genotyping and E6/E7 transcript assays for cervical lesion detection in an Asian screening population-Cobas and Aptima HPV tests.
Wong OGW; Tsun OKL; Tsui EY; Chow JNK; Ip PPC; Cheung ANY
J Clin Virol; 2018 Dec; 109():13-18. PubMed ID: 30368218
[TBL] [Abstract][Full Text] [Related]
17. Aptima HPV Assay versus Hybrid Capture
Cook DA; Smith LW; Law J; Mei W; van Niekerk DJ; Ceballos K; Gondara L; Franco EL; Coldman AJ; Ogilvie GS; Jang D; Chernesky M; Krajden M
J Clin Virol; 2017 Feb; 87():23-29. PubMed ID: 27988420
[TBL] [Abstract][Full Text] [Related]
18. Comparison of human papillomavirus detection by Aptima HPV and cobas HPV tests in a population of women referred for colposcopy following detection of atypical squamous cells of undetermined significance by Pap cytology.
Castle PE; Eaton B; Reid J; Getman D; Dockter J
J Clin Microbiol; 2015 Apr; 53(4):1277-81. PubMed ID: 25653409
[TBL] [Abstract][Full Text] [Related]
19. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer.
Ratnam S; Coutlee F; Fontaine D; Bentley J; Escott N; Ghatage P; Gadag V; Holloway G; Bartellas E; Kum N; Giede C; Lear A
J Clin Microbiol; 2011 Feb; 49(2):557-64. PubMed ID: 21147950
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Aptima and hybrid capture-2 HPV tests and Pap test in the referral population in Japan.
Kuroki H; Sakamoto J; Shibata T; Takakura M; Sasagawa T
J Med Virol; 2021 Aug; 93(8):5076-5083. PubMed ID: 33634473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]